( mulative platelet andneutrophil toxici...)Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers,Health

mulative platelet and neutrophil toxicity and mild diarrhea. Grade 1 neuropathy was observed in three patients, and no neuropathy higher than grade 1 was observed in any patients, including four patients who have received a cumulative dose >900 mg/m2. Transient grade 3-4 neutrophil toxicity occurred in 32 percent of patients and platelet toxicity in 13 percent of patients. Hematologic toxicity was more frequent in the every-two- week schedule. In the every-four-week schedule, no dose-limiting toxicity has been observed with doses of picoplatin up to 180 mg/m2. Picoplatin was administered at doses up to 90 mg/m2 every two weeks and 180 mg/m2 every four weeks. Both the biweekly and monthly regimens are still being evaluated to define their respective maximum tolerated doses.

Phase 1 HRPC Trial Data

The Phase 1 component of the HRPC trial is being conducted in patients with metastatic disease who had not previously been treated with chemotherapy. Study participants received either docetaxel 60 mg/m2 every three weeks plus prednisone 5 mg twice daily plus picoplatin or docetaxel 75 mg/m2 every three weeks plus prednisone 5 mg twice daily plus picoplatin. Picoplatin was given to sequential cohorts of subjects at 60, 80, 100 and 120 mg/m2 with docetaxel 60 mg/m2 and at 100 and 120 mg/m2 with docetaxel 75 mg/m2.

To date, 26 patients have been treated; four patients have completed 10 cycles of therapy and 15 patients remain on treatment. Therapy has been well tolerated, with transient grade 3-4 neutropenia occurring in 46 percent of patients and grade 3-4 thrombocytopenia in 8 percent of patients. Dose- limiting toxicity (grade 4 neutropenia) has been observed at 120 mg/m2 when given with 60 mg/m2 docetaxel. Dose reduction for persistent hematologic toxicity has been infrequent for doses less than 120 mg/m2 picoplatin, and there has been no cumulative myelotoxicity. Dose escalation continues with picoplatin with docetaxel at 75 mg/m2.

Planned Pha
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies